Download PDF
Int J Angiol 2021; 30(04): 262-270
DOI: 10.1055/s-0040-1722738
Original Article

Angiotensin-Receptor Blockade Improves Inflammation and Endothelial Dysfunction in Ankylosing Spondylitis: ARB-AS Study

Nidhi Garg
1   Chitkara College of Pharmacy, Chitkara University, Punjab, India
2   Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, Punjab, India
,
Pawan Krishan
2   Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, Punjab, India
,
Ashit Syngle
3   Cardio Rheuma & Healing Touch City Clinic, Chandigarh & Rheumatologist- Fortis Multi Speciality Hospital, Mohali, India
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Cardiovascular (CV) disease is the leading cause of premature death in ankylosing spondylitis (AS). Atherosclerosis and AS share similar pathogenic mechanisms. The proven benefits of angiotensin-receptor blockers (ARBs) in atherosclerotic cardiovascular disease and their role in immune mediation provide strong rationale to investigate its impact with olmesartan on inflammation and endothelial dysfunction in AS. To investigate the effect of olmesartan on inflammation and endothelial dysfunction in AS. 40 AS patients were randomized to receive 24 weeks of treatment with olmesartan (10 mg/day, n = 20) and placebo (n = 20) as an adjunct to existing stable antirheumatic drugs. Markers of endothelial function included the following: flow-mediated dilation (FMD) assessed by AngioDefender, endothelial progenitor cells (EPCs) estimated by flow cytometry, nitrite (nitric oxide surrogate), intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and inflammatory measures including Bath ankylosing spondylitis disease activity index (BASDAI), ankylosing spondylitis disease activity score (ASDAS) and bath ankylosing spondylitis functional index (BASFI); erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); proinflammatory cytokines (interleukin-1 [IL-1], IL-6, tumor necrosis factor-α [TNF-α]) and marker of oxidative stress– thiobarbituric acid reactive substances (TBARS) estimated at baseline and after treatment. Health assessment questionnaire disability index (HAQDI), 36-item short form survey (SF-36), and systematic coronary risk evaluation (SCORE) were estimated using standard tools. FMD improved significantly in the olmesartan group (5.83 ± 0.31% to 7.68 ± 0.27%, p  ≤  0.05) as compared with placebo (5.89 ± 0.35% to 6.04 ± 0.32%, p = 0.33). EPC population, nitrite, VCAM-1, and TBARS levels improved significantly in olmesartan group as compared with placebo (p ≤ 0.05). Olmesartan significantly decreased ASDAS, BASDAI, BASFI, ESR, CRP, IL-6, TNF-α, and SCORE as compared with placebo. HAQDI and SF-36 (PH) scores improved significantly in olmesartan group as compared with placebo. Olmesartan reduces inflammatory disease activity, improves quality of life (QOL), and decreases CV risk demonstrating the immunomodulatory, vasculoprotective, and cardioprotective potential of this drug in AS.

Keywords

Ankylosing Spondylitis - Endothelial Dysfunction - inflammation - Olmesartan


Publication History

Article published online:
29 January 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice?. Ther Adv Musculoskelet Dis 2013; 5 (01) 45-54
    CrossrefPubMedGoogle Scholar
  • 2 Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34 (03) 585-592
    CrossrefPubMedGoogle Scholar
  • 3 Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 2015; 163 (06) 409-416
    CrossrefPubMedGoogle Scholar
  • 4 Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007; 28 (2-3): 69-75
    CrossrefPubMedGoogle Scholar
  • 5 McCarey D, Sturrock RD. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol 2009; 27 (04, Suppl 55): S124-S126
    PubMedGoogle Scholar
  • 6 Steyers III CM, Miller Jr FJ. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci 2014; 15 (07) 11324-11349
    CrossrefPubMedGoogle Scholar
  • 7 Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369 (9568): 1208-1219
    CrossrefPubMedGoogle Scholar
  • 8 Han C, Liu J, Liu X, Li M. Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells. Atherosclerosis 2010; 212 (01) 206-212
    CrossrefPubMedGoogle Scholar
  • 9 van Eijk IC, Peters MJL, Serné EH. et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis 2009; 68 (03) 362-366
    CrossrefPubMedGoogle Scholar
  • 10 Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-α blockade. Clin Rheumatol 2010; 29 (07) 763-770
    CrossrefPubMedGoogle Scholar
  • 11 Syngle A, Vohra K, Khichi D, Garg N, Verma I, Kaur L. Spironolactone improves endothelial dysfunction in ankylosing spondylitis. Clin Rheumatol 2013; 32 (07) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 12 Sola S, Mir MQ, Cheema FA. et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111 (03) 343-348
    CrossrefPubMedGoogle Scholar
  • 13 Fliser D, Buchholz K, Haller H. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110 (09) 1103-1107
    CrossrefPubMedGoogle Scholar
  • 14 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27 (04) 361-368
    CrossrefPubMedGoogle Scholar
  • 15 Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids 2015; 2015: 971453
    CrossrefPubMedGoogle Scholar
  • 16 Hadi HAR, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007; 3 (06) 853-876
    PubMedGoogle Scholar
  • 17 Garg N, Krishan P, Syngle A. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. Clin Rheumatol 2015; 34 (06) 1065-1071
    CrossrefPubMedGoogle Scholar
  • 18 Verma I, Syngle A, Krishan P, Garg N. Endothelial progenitor cells as a marker of endothelial dysfunction and atherosclerosis in ankylosing spondylitis: a cross-sectional study. Int J Angiol 2017; 26 (01) 36-42
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem 2002; 306 (01) 79-82
    CrossrefPubMedGoogle Scholar
  • 20 Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95 (02) 351-358
    CrossrefPubMedGoogle Scholar
  • 21 Chopra A. Rheumatology: made in India (Camps, COPCORD, HLA, Ayurveda, HAQ, WOMAC and drug trials). Journal of Indian Rheumatology Association 2004; 12: 43-53
    PubMedGoogle Scholar
  • 22 Ware Jr JE. SF-36 health survey update. Spine 2000; 25 (24) 3130-3139
    CrossrefPubMedGoogle Scholar
  • 23 Agca R, Heslinga SC, Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2016; (e-pub ahead of print) DOI: 10.1136/annrheumdis-2016-209775.
    CrossrefPubMedGoogle Scholar
  • 24 Lautermann D, Braun J. Ankylosing spondylitis--cardiac manifestations. Clin Exp Rheumatol 2002; 20 (06, Suppl 28): S11-S15
    PubMedGoogle Scholar
  • 25 Sari I, Okan T, Akar S. et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45 (03) 283-286
    CrossrefPubMedGoogle Scholar
  • 26 Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010; 26 (06) 631-640
    CrossrefPubMedGoogle Scholar
  • 27 Naya M, Tsukamoto T, Morita K. et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007; 50 (12) 1144-1149
    CrossrefPubMedGoogle Scholar
  • 28 Takiguchi S, Ayaori M, Uto-Kondo H. et al. Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase. Hypertens Res 2011; 34 (06) 686-692
    CrossrefPubMedGoogle Scholar
  • 29 Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. Mol Med 2000; 6 (05) 347-373
    CrossrefPubMedGoogle Scholar
  • 30 Higashi Y, Chayama K, Yoshizumi M. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress. Curr Med Chem Cardiovasc Hematol Agents 2005; 3 (02) 133-148
    CrossrefPubMedGoogle Scholar
  • 31 Khan BV, Navalkar S, Khan QA, Rahman ST, Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 2001; 38 (06) 1662-1667
    CrossrefPubMedGoogle Scholar
  • 32 Verma I, Syngle A, Krishan P. Endothelial dysfunction in ankylosing spondylitis associated with reduced endothelial progenitor cell population. IJRCI 2015; 3 (01) OA3
    PubMedGoogle Scholar
  • 33 Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45 (04) 526-529
    CrossrefPubMedGoogle Scholar
  • 34 Imanishi T, Tsujioka H, Akasaka T. Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress. Curr Cardiol Rev 2008; 4 (04) 275-286
    CrossrefPubMedGoogle Scholar
  • 35 Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005; 109 (02) 171-176
    CrossrefPubMedGoogle Scholar
  • 36 Perry ME, Chee MM, Ferrell WR, Lockhart JC, Sturrock RD. Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67 (11) 1646-1647
    CrossrefPubMedGoogle Scholar
  • 37 Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. Egypt Heart J 2015; 67: 89-97
    CrossrefPubMedGoogle Scholar
  • 38 Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018; 9: 754
    Google Scholar
  • 39 Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52 (08) 2293-2299
    CrossrefPubMedGoogle Scholar
  • 40 Szabo SM, Levy AR, Rao SR. et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011; 63 (11) 3294-3304
    CrossrefPubMedGoogle Scholar
  • 41 Forejtová S, Mann H, Stolfa J. et al. Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol 2008; 27 (08) 1005-1013
    CrossrefPubMedGoogle Scholar